Neurology companies develop therapies, diagnostics and technologies that improve understanding and treatment of disorders affecting the brain, spinal cord and nervous system. The field addresses some of the most complex challenges in modern medicine.
This category includes companies working on:
Browse 100 UK neurology companies below.
AI-driven neural data platform for bioelectronic medicine
BIOS Health is a neural engineering company developing an AI-powered platform that reads and interprets peripheral nervous system signals in real time. Its technology links nerve…
Precision medicine biotech targeting psychiatric and neurological conditions
Monument Therapeutics is a clinical-stage biotechnology company applying precision medicine to CNS drug development. The company uses proprietary digital biomarkers to stratify…
Mitochondrial sulfide-donor therapeutics for obesity and myopathies
MitoRx Therapeutics is a company developing first-in-class small molecule therapeutics that target mitochondrial sulfide signalling, a mechanism implicated in metabolic…
Convection enhanced delivery consulting and devices for CNS therapeutics
Neurochase is a contract research and consulting organisation specialising in targeted drug delivery to the CNS using convection enhanced delivery. Working with pharmaceutical and…
Takeda's UK clinical development and drug discovery operations
Takeda UK encompasses the British operations of Takeda Pharmaceutical Company, one of the world's largest biopharmaceutical companies. The London-based Takeda Development Centre…
Specialist CRO for ion channel screening and cardiac safety assessment
Metrion Biosciences is a contract research organisation specialising in preclinical ion channel biology, cardiac safety screening, and neuroscience drug discovery services.…
Preclinical CRO for receptor pharmacology and occupancy studies
Gifford Bioscience is a contract research organisation providing receptor pharmacology and occupancy services for preclinical and discovery stage drug development. The company…
Synthetic psilocybin therapy for treatment-resistant depression and PTSD
Compass Pathways is a clinical-stage biopharmaceutical company developing synthetic psilocybin-based treatments for mental health conditions. Its lead candidate, COMP360, is a…
Tissue-targeted gene and RNA delivery platforms for rare and neurological disease
Dawn Therapeutics is a pre-clinical biotechnology company developing precision delivery platforms for genetic medicines targeting the central nervous system, cartilage, and bone.…
NLRP3 inflammasome inhibitors for chronic inflammatory disease
NodThera is a clinical-stage biotechnology company developing potent and selective small molecule inhibitors of the NLRP3 inflammasome for diseases driven by chronic inflammation.…
Exosome-delivered gene editing therapies for neurodegenerative diseases
Evox Therapeutics is a biotechnology company developing exosome-based gene editing therapies for rare, genetically driven neurodegenerative diseases. Its proprietary platform uses…
Perfluorocarbon oxygen carrier therapeutic and MRI imaging agent for acute stroke
Aurum Biosciences is a Scottish clinical-stage biopharmaceutical company developing ABL-101, a perfluorocarbon-based oxygen carrier that bypasses arterial clots to deliver oxygen…